The Orphan Drug Act and Catalyst Pharmaceuticals, Inc., v. Becerra

Research ReportCRS ReportVersion 2

R47653

The Orphan Drug Act and Catalyst Pharmaceuticals, Inc., v. Becerra

Published Aug 17, 2023Updated Jun 21, 2025

Full report

What this is

The Congressional Research Service is a nonpartisan policy and legal analysis arm of the Library of Congress. CRS reports are written for members of Congress and their staff, not the public — but they’re made available openly through Congress.gov.

Read the PDF on Congress.gov

HR 2430115th Congress
FDA Reauthorization Act of 2017
Aug 18, 2017 · Signed by President.
HR 523897th Congress
Orphan Drug Act
Jan 4, 1983 · Became Public Law No: 97-414.

The Orphan Drug Act and Catalyst Pharmaceuticals, Inc., v. Becerra

Legislation this report covers